Employment of higher doses of botulinum toxin type A to reduce spasticity after stroke

Journal of the Neurological Sciences

Volumn 350, Issue 1-2, 2015, Pages 1-6

  Santamato, Andrea ^a   Micello, Maria Francesca ^a   Ranieri, Maurizio ^a   Valeno, Giovanni ^a   Albano, Antonio ^a   Baricich, Alessio ^b   Cisari, Carlo ^b   Intiso, Domenico ^c   Pilotto, Alberto ^c,d   Logroscino, Giancarlo ^e   Panza, Francesco ^c,e  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^d S ANTONIO HOSPITAL   (Italy)

^e UNIVERSITY OF BARI   (Italy)

Author keywords

Lower limb spasticity; Neurotoxins; Nontraumatic acquired brain injury; Upper limb spasticity; Upper motor neuron syndrome

Indexed keywords

BOTULINUM TOXIN A;

CEREBROVASCULAR ACCIDENT; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DYSARTHRIA; FATIGUE; GAIT DISORDER; HUMAN; INJECTION SITE PAIN; LIMB WEAKNESS; META ANALYSIS (TOPIC); MUSCLE WEAKNESS; PARESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPASTICITY; TREATMENT OUTCOME; COMPLICATION; MUSCLE SPASTICITY; PROCEDURES; STROKE;

BOTULINUM TOXINS, TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MUSCLE SPASTICITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 84933179321     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2015.01.033     Document Type: Review

References (37)

1. Sheean G. The pathophysiology of spasticity. Eur J NeurolMay 2002;9(Suppl. 1):3-9.
2. Smania N, Picelli A, Munari D, Geroin C, Ianes P, Waldner A, et al. Rehabilitation procedures in the management of spasticity. Eur J Phys Rehabil Med Sep 2010; 46(3):423-38.
3. Rosales RL, Chua-Yap AS. Evidence-based systematic reviewon the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity. J Neural Transm 2008;115: 617-23.
4. Truong D, Dressler D, Hallett M. Manual of botulinum toxin therapy. Cambridge: Cambridge University Press; 2009.
5. Wissel J, Ward AB, Erztgaard P, Bensmail D, Hecht MJ, Lejeune TM, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med 2009;41:13-25.
6. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987;67:206-7.
7. Aoki KR. Reviewof a proposedmechanismfor the antinociceptive action of botulinum toxin type A. Neuro Toxicology 2005;26:785-93.
8. Crowner BE, Torres-Russotto D, Carter AR, Racette BA. Systemic weakness after therapeutic injections of botulinumtoxin a: a case series and reviewof the literature. Clin Neuropharmacol 2010;33:243-7.
9. Varghese-Kroll E, Elovic EP. Contralateral weakness and fatigue after high-dose botulinum toxin injection for management of poststroke spasticity. Am J Phys Med Rehabil 2009;88:495-9.
10. Thomas AM, Simpson DM. Contralateral weakness following botulinum toxin for poststroke spasticity. Muscle Nerve 2012;46:443-8.
11. Yablon SA, Brashear A, Gordon MF, Elovic EP, Turkel CC, Daggett S, et al. Formation of neutralizing antibodies in patients receiving botulinumtoxin type A for treatment of post stroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther 2007; 29:683-90.
12. Bakheit AM, Liptrot A, Newton R, Pickett AM. The effect of total cumulative dose, number of treatment cycles, interval between injections, and length of treatment on the frequency of occurrence of antibodies to botulinum toxin type A in the treatment of muscle spasticity. Int J Rehabil Res 2012;35:36-9.
13. Albanese A. Terminology for preparations of botulinumneurotoxins:what a difference a name makes. JAMA 2011;305:89-90.
14. Park J, Lee MS, Harrison AR. Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm. Clin Ophthalmol 2011;5:725-32.
15. Dressler D, Mander GJ, Fink K. Equivalent potency of Xeomin® and Botox®. Mov Disord 2008;23(Suppl.1):S20-1.
16. Dressler D, Mander G, Fink K. Measuring the potency labelling of onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)) in an LD50 assay. JNeural Transm 2012;119:13-5.
17. Roggenkamper P, Jost WH, Bihari K, Comes G, Grafe S. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 2006;113:303-12.
18. Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S. A newbotulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005;64:1949-51.
19. Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox® in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998;64:6-12.
20. Dressler D. Routine use of Xeomin® in patients previously treated with Botox®: long term results. Eur J Neurol 2009;16(Suppl. 2):2-5.
21. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of Botox® and Dysport®: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;72:459-62.
22. Hesse S, Jahnke MT, Luecke D, Mauritz KH. Short-term electrical stimulation enhances the effectiveness of Botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett 1995;201:37-40.
23. Santamato A, Panza F, Ranieri M, Frisardi V, Micello MF, Filoni S, et al. Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke. J Neural Transm 2013; 120:469-76.
24. Intiso D, Simone V, Di Rienzo F, Iarossi A, Pazienza L, Santamato A, et al. High doses of a new botulinum toxin type A (NT-201) in adult patients with severe spasticity following brain injury and cerebral palsy. Neuro Rehabilitation 2014;34:515-22.
25. Dressler D, Adib Saberi F, Kollewe K, Schrader C. Safety aspects of incobotulinumtoxinA high-dose therapy. J Neural Transm 2014. http://dx.doi.org/10.1007/s00702-014- 1252-9 [Epub ahead of print].
26. Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists Interested in Neurology. Spasticity in adults: management using botulinum toxin. National guidelines. London: RCP; 2009.
27. Lange DJ, Brin MF, Warner CL, Fahn S, Lovelace R. Distant effects of local injection of botulinum toxin. Muscle Nerve 1987;10:552-5.
28. Olney RK, Aminoff MJ, Gelb DJ. Lowenstein DH (1988) Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology 1988;38:1780-3.
29. Girlanda P, Vita G, Nicolosi C, Milone S, Messina. Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry 1992;55:844-5.
30. Bakheit AM, Ward CD, McLellan DL. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases. J Neurol Neurosurg Psychiatry 1997;62:198.
31. Mayer NH, Simpson DM, editors. Spasticity: etiology, evaluation, management, and the role of botulinum toxin type A. 3rd ed. New York: We Move; 2005.
32. Jost WH, Blümel J, Grafe S. Botulinumneurotoxin type A free of complexing proteins (XEOMIN®) in focal dystonia. Drugs 2007;67:669-83.
33. Picelli A, Tamburin S, Bonetti P, Fontana C, Barausse M, Dambruoso F, et al. Botulinum toxin type A injection into the gastrocnemius muscle for spastic equinus in adults with stroke: a randomized controlled trial comparing manual needle placement, electrical stimulation and ultrasonography-guided injection techniques. Am J Phys Med Rehabil 2012;91:957-64.
34. Picelli A, Lobba D, Midiri A, Prandi P, Melotti C, Baldessarelli S, et al. Botulinum toxin injection into the forearm muscles for wrist and fingers spastic overactivity in adults with chronic stroke: a randomized controlled trial comparing three injection techniques. Clin Rehabil 2014;28:232-42.
35. Radensky PW, Archer JW, Dournaux SF, O'Brien CF. The estimated cost of managing focal spasticity: a physician practice patterns survey. Neurorehabil Neural Repair 2001;15:57-68.
36. Shackley P, Shaw L, Price C, van Wijck F, Barnes M, Graham L, et al. Cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A: results from the botulinum toxin for the upper limb after stroke (BoTULS) trial. Toxins (Basel) 2012;4:1415-26.
37. Ward A, Roberts G, Warner J, Gillard S. Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity. J Rehabil Med 2005;37:252-7.